Introduction {#Sec1}
============

Multiple pathological derangements contribute to the chronic hyperglycemia and hypertriglyceridemia that characterize type 2 diabetes mellitus (T2DM) \[[@CR1]--[@CR3]\]. Although specific details may vary in individual patients, these pathological defects can occur in the following organs and tissues: skeletal muscle, which becomes less effective at absorbing glucose after a meal; liver, which releases too much glucose into the blood during fasting; pancreatic beta-cells, which fail to produce enough insulin to maintain normoglycemia (despite overexpressing the hormone relative to healthy patients); pancreatic alpha-cells, which secrete excess glucagon; adipose tissue, which secretes excess lipids; the gastrointestinal tract, which secretes reduced levels of incretin factors; and the kidney, which reabsorbs too much glucose (Fig. [1](#Fig1){ref-type="fig"}). All told, these derangements combine to drive up blood sugar and serum lipids and, in so doing, dramatically raise the risk of macrovascular and microvascular events.Fig. 1Pathophysiologic disturbances in T2DM that may lead to hyperglycemia and the sites of action of antidiabetes medications. Incretin therapy includes glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Despite the complexities of this clinical picture, the pathophysiological defects underlying T2DM can be attributed in large part to a single core defect, that is, inappropriate resistance to the biologic effects of insulin \[[@CR1], [@CR2]\]. The mechanism by which insulin resistance develops in various tissues, a process that involves alterations in cellular signal transduction pathways and receptors/transporters in the affected tissues \[[@CR4]\], is beyond the scope of this review. Nonetheless, it is important to note that one of the key features of insulin resistance is its progression over time \[[@CR5]\], which results in beta-cells producing increasingly more insulin to compensate. Ultimately, however, because their synthetic capacity becomes exhausted, because they are damaged by increased levels of serum lipids, or for reasons as yet unknown \[[@CR6]\], beta-cells eventually lose the ability to produce sufficient insulin, and insulin replacement therapy may become necessary.

Managing this complex and evolving clinical picture can be extremely challenging. The most commonly used antidiabetic medications include metformin, sulfonylureas, thiazolidinediones, incretin therapies \[glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors\], sodium-glucose co-transporter 2 (SGLT2) inhibitors, and basal and bolus insulins \[[@CR7]\]. Three treatment approaches have been published recently that recommend how to combine these therapies to achieve optimal glucose control \[[@CR3], [@CR7], [@CR8]\]. All recommend that therapeutic regimens for T2DM should be chosen, in part, based on an understanding of the underlying pathophysiology. In particular, they recommend medications for polytherapy that complement one another, i.e., have different targets among the organs and tissues most affected in T2DM. Fortunately, the armamentarium of available antidiabetes medications now contains individual agents that target virtually all of these organs and tissues (Fig. [1](#Fig1){ref-type="fig"}).

Methods {#Sec2}
=======

This review will examine the role of one class of antidiabetes medications, the GLP-1RAs, with a particular focus on the newest member of the class, exenatide once weekly (exenatide QW). It will attempt to rationalize exenatide QW use in terms of the underlying pathology and its pharmacology. The potential value of the new once-weekly treatment modality will also be discussed. Relevant literature was identified through PubMed database searches from inception until September 2013. Search terms included exenatide, glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes mellitus, diabetes pathophysiology, and other terms specifically associated with individual sections of the review.

Compliance with Ethics {#Sec3}
----------------------

The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author.

Discussion {#Sec4}
==========

Pharmacology {#Sec5}
------------

Three GLP-1RAs, exenatide twice daily (exenatide BID) \[[@CR9]\], liraglutide once daily (liraglutide QD) \[[@CR10]\], and exenatide QW \[[@CR11]\] are currently available in the USA for treating T2DM. All three lower blood glucose by replicating the activity of GLP-1, a naturally occurring hormone released from intestinal L cells in response to a meal \[[@CR12], [@CR13]\]. Native GLP-1 acts in an endocrine and/or paracrine fashion to restore euglycemia by multiple mechanisms. These mechanisms include stimulating insulin secretion from pancreatic beta-cells \[[@CR12]\]; inhibiting glucagon secretion from pancreatic alpha-cells in the presence of elevated blood glucose levels \[[@CR14], [@CR15]\]; decreasing gastric motility to slow nutrient absorption \[[@CR16]\]; and inducing feelings of satiety \[[@CR17]\] (Fig. [1](#Fig1){ref-type="fig"}).

Exenatide is a 39-amino acid synthetic version of exendin-4, a peptide isolated from the lizard *Heloderma suspectum* \[[@CR18]\]. The drug shares 53% sequence identity with human GLP-1 \[[@CR13]\] and consequently binds with high affinity to GLP-1 receptors, thereby inducing all of its known glucoregulatory activities \[[@CR19]--[@CR21]\]. However, exenatide is more resistant to the activity of DPP-4 \[[@CR18]\], a widely dispersed protease that rapidly cleaves native GLP-1 in vivo \[[@CR22]\]. The first exenatide formulation manufactured for clinical use, known now as exenatide BID, remains at therapeutic concentrations within the bloodstream long enough to allow for twice-daily subcutaneous administration before the two main meals of the day \[[@CR9]\]. Liraglutide QD, a modified form of mammalian GLP-1 that contains an amino acid substitution at position 34 and an added C16 palmitoyl fatty-acid side chain at position 26, remains at therapeutic concentrations long enough in vivo---with an elimination half-life of approximately 13 h, in part because it is injected at very high concentrations (1.2 or 1.8 mg per administration)---to allow for once-daily administration \[[@CR10]\].

In the new once-weekly formulation of exenatide, the exenatide molecule is dispersed in microspheres \[[@CR11], [@CR23]--[@CR26]\]. Following subcutaneous administration, these microspheres undergo spontaneous hydrolysis into lactic and glycolic acids, which are easily eliminated as carbon dioxide and water. During this process, active drug is slowly released into circulation \[[@CR23]\]. The combined release of exenatide from multiple once-weekly injections results in consistent blood concentrations over time, well above the level demonstrated to impart full pharmacologic effect \[[@CR27]\].

Efficacy {#Sec6}
--------

Six randomized controlled clinical trials, known by the acronym DURATION (Diabetes Therapy Utilization: Researching Changes in A1c, Weight and Other Factors Through Intervention with Exenatide Once Weekly), have been conducted on exenatide QW, each lasting 24--30 weeks \[[@CR28]--[@CR33]\] (Table [1](#Tab1){ref-type="table"}). In total, 3,225 patients with T2DM were assessed, of whom 1,379 received exenatide QW and 1,846 received comparators. Comparators included metformin, pioglitazone, sitagliptin, insulin glargine, exenatide BID, and liraglutide QD. In the trials, exenatide QW was assessed either as monotherapy or in combination with metformin, sulfonylureas, thiazolidinediones, or combinations of these agents.Table 1Exenatide once-weekly efficacy in the DURATION study programDURATION-4 \[[@CR1]\]DURATION-2 \[[@CR2]\]DURATION-1 \[[@CR3]\]DURATION-5 \[[@CR4]\]DURATION-6 \[[@CR5]\]DURATION-3 \[[@CR6]\]Background therapy:D/E aloneMETD/E alone ± MET, SFU, or TZD (or combos)MET ± SFUExenatide QW2 mg QW2 mg QW2 mg QW2 mg QW2 mg QW2 mg QWComparator(s)MET\
PIO\
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Exenatide QW Monotherapy {#Sec7}
------------------------

Based on its relative cost compared with antidiabetic agents available generically, as well as its subcutaneous route of administration, exenatide QW may not be commonly thought of as first-line monotherapy, although indicated as an adjunct to diet and exercise in adults with T2DM \[[@CR11]\]. This is consistent with the recent Standards of Medical Care in Diabetes from the American Diabetes Association, which recommend first-line metformin followed by optional second-line treatment with a GLP-1RA \[[@CR7]\]. A second algorithm for antidiabetes therapy, known as the "pathophysiologic approach," recommends avoiding monotherapy altogether, instead advocating initiation with a combination of metformin, a thiazolidinedione, and a GLP-1RA \[[@CR3]\]. The American Association of Clinical Endocrinologists (AACE) indicates that GLP-1RAs are appropriate options as monotherapy in patients who start pharmacotherapy with an entry glycated hemoglobin (Hb)A1c \<7.5%; in patients who start initial pharmacotherapy at higher HbA1c levels, the GLP-1RAs are recommended as first options in dual therapies (entry HbA1c ≥7.5%) or triple therapies (entry HbA1c ≥9.0%) \[[@CR8]\].

The DURATION-4 study directly compared exenatide QW monotherapy with metformin monotherapy and pioglitazone monotherapy (an additional arm with sitagliptin will be described in the next section). Results showed that long-term control appeared similar for all three agents \[[@CR32]\] (Table [1](#Tab1){ref-type="table"}). Thus, in patients suboptimally controlled on diet and exercise, changes from baseline in HbA1c after 26 weeks of therapy with exenatide QW, metformin, or pioglitazone were −1.5%, −1.5%, and −1.6%, respectively (*p* = NS for all comparisons). Similarly, changes from baseline in fasting plasma glucose (FPG) were, respectively, −41.4, −36.0, and −46.8 mg/dL (*p* = not significant (NS) for all comparisons). Therapy with exenatide QW, however, appeared to be distinguishable by other effects. For example, exenatide QW, unlike metformin, significantly slowed down the time-dependent loss of glucose control in T2DM. This was shown in an extension study of DURATION-3, which demonstrated that patients on exenatide QW maintained most of their HbA1c reductions for at least 3 years \[[@CR34]\]. Moreover, therapy with exenatide QW resulted in moderate weight loss (Table [1](#Tab1){ref-type="table"}).

Exenatide QW Combination Therapy {#Sec8}
--------------------------------

As described above, current guidelines recommend that polytherapy for T2DM should consist of individual agents that act in concert on different aspects of the underlying pathophysiology. Implicit in this recommendation is the notion that hyperglycemia in T2DM arises from accumulated incremental effects of dysregulation across all of the involved organs and tissues. Consequently, addressing as many pathophysiological problems as possible would be assumed, according to this model, to have the greatest impact on blood sugar. The most direct test of this assumption would be to compare outcomes in treatment-naive subpopulations started on one, two, three, or more therapies. Only a few studies with GLP-1RAs have taken this, or a similar, approach \[[@CR35]--[@CR37]\].

Most drug trials have taken a different approach. Their basic design involves administering the test agent of interest to a population of patients who are no longer achieving optimal glucose control on a pre-existing regimen of background therapy. Again, this would be expected to successfully lower blood glucose only if the individual agents that compose the regimen act, at least partially, on independent targets. DURATION-1, -2, -3, -5, and -6 have all taken this approach \[[@CR28]--[@CR31], [@CR33]\], and in each case, the addition of exenatide QW to suboptimal background therapy significantly improved glycemic parameters (Table [1](#Tab1){ref-type="table"}). Thus, in general, the addition of exenatide QW to other classes of antidiabetic medications provided significant add-on therapeutic benefit in T2DM.

Several other conclusions can be drawn from the results of the DURATION study program. First, although similar in many respects, exenatide QW and exenatide BID should not be considered directly interchangeable. DURATION-1 \[[@CR31]\] and DURATION-5 \[[@CR29]\] examined the effects of these two agents on patients who were achieving suboptimal control on diet and exercise alone ± metformin, a sulfonylurea, a thiazolidinedione, or a combination of the prior agents. In DURATION-1, exenatide QW was associated with greater reductions than exenatide BID in HbA1c (−1.9% vs. −1.5%, *p* = 0.0023) and FPG (−41.4 vs. −25.2 mg/dL, *p* \< 0.0001). Conversely, reductions from baseline in 2-h postprandial glucose (PPG) levels were significantly greater with exenatide BID than exenatide QW. Similar observations were made in DURATION-5. These results have led some to suggest that the twice-daily formulation, which has its strongest effect on PPG, is a particularly ideal "fit" with basal insulin, which primarily affects FPG \[[@CR38]\]. The hypothesis was confirmed in a recently published randomized clinical trial, which showed that the addition of exenatide BID to titrated basal insulin provided greater glycemic control than titrated basal insulin alone, and did so without an increase in hypoglycemic events and with modest weight loss \[[@CR39]\]. Studies are currently ongoing to examine the effect of exenatide QW in combination with basal insulin.

Another study directly compared exenatide QW and titrated basal insulin, and the results constitute a second key finding of the DURATION study program. In DURATION-3 \[[@CR30]\], patients inadequately controlled on background metformin ± a sulfonylurea exhibited greater reductions in HbA1c (−1.5% vs. −1.3%; *p* = 0.0003), but smaller reductions in FPG (−37.8 vs. −50.4 mg/dL; *p* = 0.001), after 26 weeks of therapy with exenatide QW relative to basal insulin. After 3 years of therapy, HbA1c reductions remained greater in the exenatide QW group (−1.01% vs. 0.81%; *p* = 0.03) and FPG reductions remained less (−31.1 vs. 47.7 mg/dL; *p* \< 0.001) \[[@CR34]\]. Patients on exenatide QW also exhibited weight loss, whereas those on basal insulin exhibited weight gain (Table [1](#Tab1){ref-type="table"}). Thus, from an efficacy perspective, long-term use of exenatide QW was at least as effective as basal insulin. This result may appear unexpected at first, given that therapeutic insulin can be dosed to produce virtually any desired blood glucose value \[[@CR1], [@CR2]\]. However, intensive insulin therapy is limited by concerns over hypoglycemic episodes, which correlate with overall mortality \[[@CR40]--[@CR42]\]; hypoglycemia is not as great a concern with exenatide QW (see "[Safety](#Sec9){ref-type="sec"}", below).

A third key point from the DURATION study program is that exenatide QW and the DPP-4 inhibitor sitagliptin did not have identical activities, despite the fact that both agents come under the general rubric of incretin therapies. Both as monotherapy and in combination with metformin, exenatide QW was associated with greater reductions in HbA1c, FPG, and weight than sitagliptin (Table [1](#Tab1){ref-type="table"}). For instance, in the 26-week DURATION-4 monotherapy trial \[[@CR32]\], the exenatide QW and sitagliptin groups experienced reductions in HbA1c of −1.5% and --1.2%, respectively (*p* \< 0.001); in FPG of −41.4 and −19.8 mg/dL (*p* \< 0.001); and in weight of −2.0 kg and −0.8 kg (*p* \< 0.001). This likely reflects the underlying pharmacology of the two agents. Pharmacokinetic experiments have demonstrated that overall exposure to endogenous GLP-1 increases approximately twofold in patients on DPP-4 inhibitors and that blood hormone levels fluctuate up and down between postprandial and fasting states, similar to what occurs in drug-naive healthy individuals \[[@CR43]\]. By contrast, repeated administrations of exenatide QW resulted in essentially constant and high levels of active agent \[[@CR27]\]. Thus, in thinking how to distinguish between the two agents, clinicians should consider the clinical effect on HbA1c and weight, as well as tolerability profile and administration route.

Finally, in DURATION-6 \[[@CR33]\], exenatide QW appeared to have lower efficacy than liraglutide QD. Across the 26-week study period in the exenatide QW and liraglutide QD groups, HbA1c decreased by −1.3% and −1.5%, respectively (*p* = 0.02); FPG decreased by −31.7 and −38.2 mg/dL (*p* = 0.02); and weight decreased by −2.7 and −3.6 kg (*p* = 0.005). As with the exenatide QW and sitagliptin comparison, a clinician choosing between exenatide QW and liraglutide QD should consider clinical efficacy, but also dosing convenience and tolerability (see [Safety](#Sec9){ref-type="sec"}, below).

Safety {#Sec9}
------

The bulk of safety data on exenatide QW derives from the DURATION study program, which consisted of trials lasting between 24 and 30 weeks. The information provided in this section summarizes these data, but it should be borne in mind that longer-term side effects, if any, remain to be determined.

Gastrointestinal Effects {#Sec10}
------------------------

Gastrointestinal side effects are the primary tolerability issue with GLP-1RAs, including exenatide QW (Table [2](#Tab2){ref-type="table"}). In the DURATION study program, the most common gastrointestinal adverse event, mild to moderate nausea, occurred at rates ranging from 9.3% to 26.4% across all studies. Reported cases of nausea occurred predominantly in the first 6--8 weeks of therapy and tapered off significantly thereafter \[[@CR23]\]. In direct head-to-head comparisons, exenatide QW was associated with significantly less nausea than either exenatide BID or liraglutide QD. In DURATION-6, rates of nausea in patients on exenatide QW and liraglutide QD were 9.3% and 20.7%, respectively. The greater gastrointestinal tolerability of exenatide QW relative to the other GLP-1RAs likely reflects its pharmacokinetic properties, specifically the more gradual rise in active agent in the blood that occurs after initiating the once-weekly formulation relative to other GLP-1RAs \[[@CR44]\].Table 2Rates of gastrointestinal adverse events associated with incretin therapies in the DURATION study programNausea (%)Diarrhea (%)Vomiting (%)Constipation (%)DURATION-1 Exenatide QW26.413.510.810.8 Exenatide BID34.513.118.66.2DURATION-2 Exenatide QW2418116 Sitagliptin101022DURATION-4 Exenatide QW11.310.9NR8.5 Sitagliptin3.75.5NR2.5DURATION-5 Exenatide QW14.09.34.7NR Exenatide BID35.04.18.9NRDURATION-6 Exenatide QW9.36.13.74.6 Liraglutide QD20.713.110.74.9*DURATION* Diabetes Therapy Utilization: Researching Changes in A1c, Weight and Other Factors Through Intervention with Exenatide Once Weekly, *exenatide BID* exenatide twice daily, *exenatide QW* exenatide once weekly, *NR* not reported

Hypoglycemia {#Sec11}
------------

No episodes of major hypoglycemia were documented in patients on exenatide QW in any of the DURATION trials \[[@CR28]--[@CR33]\]. Moreover, the incidence of minor hypoglycemia (defined as a plasma glucose concentration \<54 mg/dL) was 2.0% in patients who received exenatide QW as monotherapy or in combination with metformin or a thiazolidinedione (Amylin Pharmaceuticals, data on file). These results are consistent with the known properties of exenatide vis-à-vis insulin secretion. In hyperinsulinemic--hypoglycemic clamp experiments, intravenous exenatide was shown to maximally stimulate insulin secretion when blood glucose was above 90 mg/dL (5 mmol/L) \[[@CR45]\]. As blood glucose declined below this level toward the euglycemic range, insulin secretory rates declined as well, eventually becoming indistinguishable from those of the control placebo patients when glycaemia reached 72 mg/dL (4 mmol/L). In other words, exenatide-induced insulin secretion is glucose dependent and, thus, occurs mainly in the presence of hyperglycemia. By contrast, insulin and insulin secretagogues, such as sulfonylureas, continue to reduce blood sugar even after blood glucose has fallen into the hypoglycemic range. Consequently, in clinical trials, sulfonylureas in combination with exenatide QW were observed to result in higher levels of hypoglycemia \[[@CR23]\]. In patients receiving this combination, it is therefore recommended that the sulfonylurea dosage be carefully monitored and reduced if necessary \[[@CR11]\].

Cardiovascular Effects {#Sec12}
----------------------

Ever since a potential association was observed between rosiglitazone use and elevated cardiovascular (CV) risk \[[@CR46]\], as well as between intensive antidiabetic therapy and adverse cardiac outcomes in some patients \[[@CR47]\], all antidiabetic medications have come under increased surveillance for CV safety, including long-term post-marketing safety studies \[[@CR48]\]. Exenatide QW is currently undergoing such studies, although the results are not yet available. Definitive conclusions must await the results, but three current observations suggest a significant CV signal may not be expected. First, clinical studies on exenatide at therapeutic and supra-therapeutic concentrations did not prolong QTc interval in healthy subjects \[[@CR49]\]. A similar lack of effect was observed in another trial on exenatide QW \[[@CR50]\]. Second, in multiple DURATION studies, exenatide QW therapy was associated with moderate improvements in systolic blood pressure and blood lipids \[[@CR28]--[@CR33]\]. Third, meta-analyses of short-term studies with exenatide BID identified no increased CV risk \[[@CR51]\].

Pancreatic Effects {#Sec13}
------------------

The potential association between incretin therapies, both GLP-1RAs and DPP-4 inhibitors, and pancreatic effects has received significant attention recently \[[@CR52], [@CR53]\]. The concern initially came to light in a published work that found elevated rates of spontaneously reported pancreatitis and pancreatic cancer in the US Food and Drug Administration's (FDA's) Adverse Event Reporting System among patients on incretin therapies \[[@CR54]\]. This analysis, however, has come under significant criticism for its dependence on uncontrolled and spontaneously reported events and for its bias in focusing exclusively on pancreatic events. A subsequent analysis of the same database found that whereas spontaneous reports of pancreatic cancer were indeed higher, reports of several other cancers were significantly *lower* in incretin users \[[@CR55]\]. Interpretations of the data are further complicated by the fact that T2DM per se is associated with increased risk of pancreatitis. A retrospective study of diabetic patients (*n* **=** 337,067) and age- and sex-matched nondiabetic patients (*n* **=** 337,067) found a pancreatitis incidence rate of 4.22 cases per 1,000 patient-years in the diabetic cohort versus 1.49 cases per 1,000 patient-years in the nondiabetic cohort \[[@CR56]\]. Pancreatitis risk may also be increased in the setting of obesity, another common complication of T2DM \[[@CR57]\].

Ultimately, the potential role, if any, of incretin therapies in pancreatic side effects will require long-term post-marketing observational trials designed to directly assess this question. These studies are ongoing for multiple incretin therapies, and results have begun to be reported. The results appear encouraging. The rates of pancreatitis among patients on the DPP-4 inhibitors saxagliptin and alogliptin were statistically indistinguishable from those among patients on other antidiabetic agents \[[@CR58], [@CR59]\]. Similar prospective data have not yet been reported for GLP-1RAs, but a retrospective study of a large insurance claims database came to a similar conclusion for exenatide \[[@CR60]\]. The absolute risk of acute pancreatitis among exenatide initiators was 0.13% (37 cases among 27,995 patients followed for up to 1 year), which was equivalent to the absolute risk in a propensity score-matched cohort of metformin/glyburide initiators (0.13%; 36 cases per 27,983 patients).

A report from the European Medicines Agency concluded that present data do not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based therapies \[[@CR61]\]. The FDA concurred in this conclusion \[[@CR62]\]. Exenatide QW has not been studied in patients with a history of pancreatitis, however \[[@CR11]\]. Consequently, until prospective studies become available, it is prudent to follow the recommendations on the package insert, i.e., discontinue therapy with exenatide QW in patients with pancreatitis and consider other classes of antidiabetic medications in patients with a history of pancreatitis.

Use in Patients with Renal Impairment and the Elderly {#Sec14}
-----------------------------------------------------

Managing systemic therapy in the setting of renal impairment, which is associated with both increasing duration of T2DM and age, is a significant challenge. Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration \[[@CR11], [@CR63]\], making this issue one of particular relevance to patients on exenatide QW. In clinical trials, severe nausea, severe vomiting, and rapidly declining blood glucose concentrations, including severe hypoglycemia requiring parenteral glucose administration, were associated with overdoses of exenatide BID \[[@CR11]\], although it should be noted that overdose is extremely unlikely with the single-use administration device for exenatide QW.

Based on the prior considerations, exenatide QW should not be used in patients with severe renal impairment (creatinine clearance \<30 mL/min) or end-stage renal disease. As the injector apparatus for exenatide QW comes pre-packaged with a single, fixed amount of agent for subcutaneous administration, decreasing its dosage is not an option. Instead, in patients on exenatide QW who have mild to moderate renal impairment (creatinine clearance 30--50 mL/min), down-titration of concomitant medications, in particular sulfonylureas, may become necessary to manage hypoglycemia and other adverse events.

Post-marketing case reports of worsened kidney function associated with exenatide use have raised concern over a causal relationship \[[@CR11]\]. However, as with the potential pancreatic effects described above, drawing conclusions from spontaneous reports is highly problematical. A recent meta-analysis examined six randomized trials (16--30 weeks) comparing exenatide BID (*n* = 905) with placebo (*n* = 916) and two similar trials (24--30 weeks) comparing exenatide BID (*n* = 268) with exenatide QW (*n* = 277) \[[@CR64]\]. Overall, across the trials, the decline in glomerular filtration rates did not differ between the comparators. Thus, to date, a claim of a causal link between exenatide use and worsening kidney function remains unsupported. This is consistent with another analysis, which failed to find any clinically significant differences among elderly patients who participated in the DURATION study program \[[@CR65]\], although it is important to bear in mind that the trials excluded patients with severe renal impairment.

Adherence and Cost {#Sec15}
------------------

Exenatide QW was formulated to increase patient convenience by decreasing the frequency of injections. However, no post-marketing studies have yet assessed whether this added convenience translates into higher treatment compliance. In general terms, though, studies have confirmed that adherence to antidiabetic regimens remains unsatisfactory \[[@CR66]\] and that ease of administration results in higher treatment compliance \[[@CR67]\]. A more directly relevant study surveyed 1,516 adults with T2DM and assessed their perceptions of a once-weekly medication \[[@CR68]\]. The results showed that positive attitudes regarding a once-weekly dosing regimen were common, with beneficial aspects perceived to include greater convenience, better medication adherence, improved quality of life, and a less overwhelming sense of treatment (*p* \< 0.001 for all comparisons). Approximately, 47% of surveyed patients reported they would likely take an injectable once-weekly medication if recommended by their physician, with current injection users more than twice as likely as non-injection users (73.1% vs. 31.5%; *p* \< 0.001).

Cost--benefit analyses have been performed for exenatide QW relative to exenatide BID \[[@CR69]\], insulin glargine \[[@CR69]--[@CR72]\], sitagliptin \[[@CR73]\], and pioglitazone \[[@CR73]\]. In general, exenatide QW was predicted to be cost effective relative to insulin glargine, as measured by quality-adjusted life years, in the healthcare systems of the UK, Spain, Switzerland, and the USA \[[@CR69]--[@CR72]\]. Similarly, in a validated computer model, exenatide QW was projected to improve health and reduce lifetime costs for diabetes-related complications compared with sitagliptin or pioglitazone \[[@CR73]\].

Conclusion {#Sec16}
==========

It is currently recommended that optimal antidiabetic polytherapy should use therapeutic agents that act in concert on different aspects of T2DM. By this criterion, exenatide QW, like other GLP-1RAs, is an attractive option, as it affects multiple organs and tissues involved in the etiology of the disease. An increasing body of literature has demonstrated that exenatide QW provides reductions in HbA1c with little risk of hypoglycemia, and does so while simultaneously providing moderate weight loss. The primary safety issues associated with its use are gastrointestinal side effects, whereas other risks of recent concern, including CV, pancreatic, and kidney effects, appear small and manageable based on available evidence. In general, the efficacy of exenatide QW appeared to be greater than that of the DPP-4 inhibitor sitagliptin \[[@CR28], [@CR32]\] and slightly less than that of the GLP-1RA liraglutide QD \[[@CR37]\]. On the other hand, the incidence of gastrointestinal events of exenatide QW appeared to be lower than that of liraglutide QD and higher than that of sitagliptin. Thus, exenatide QW may be particularly well suited to patients who desire the benefits associated with glucagon-like peptide-1 receptor agonists, including significant glycemic control, low risk of hypoglycemia, and moderate weight loss, but prefer the convenience of once-weekly dosing.
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